Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for
their growth. Hormone therapy using tamoxifen may fight breast cancer by blocking the use of
estrogen by the tumor cells. Combining gefitinib with tamoxifen may be effective in killing
tumor cells that have become resistant (stopped responding) to tamoxifen.
PURPOSE: This randomized phase II trial is studying how well giving gefitinib together with
tamoxifen works compared to gefitinib alone in treating patients with metastatic breast
cancer that has stopped responding to tamoxifen.
Phase:
Phase 2
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborators:
National Cancer Institute (NCI) Norris Cotton Cancer Center